ac

Revolutionizing Pharmaceutical Research: Harnessing Machine Learning for a Paradigm Shift in Drug Discovery

Authors

  • Ali Husnain Chicago State University, USA
  • Saad Rasool 2 Department of computer science, Concordia University Chicago, 7400 Augusta St, River Forest, IL 60305, United States
  • Ayesha Saeed University of Lahore, Pakistan
  • Hafiz Khawar Hussain DePaul University Chicago, Illinois, USA

DOI:

10.47709/ijmdsa.v2i2.2897

Keywords:

clinical trials, target identification, predictive modeling, ADMET profiling, machine learning, pharmaceutical research, compound screening, ethical considerations, personalized medicine, data privacy, and future prospects.

Dimension Badge Record



Abstract

The fusion of machine learning (ML) and artificial intelligence (AI) is experiencing a dramatic transition in the field of pharmaceutical research and development. This study examines the several effects of machine learning (ML) on different phases of medication discovery, development, and patient care. The capability of ML to quickly process huge chemical libraries and forecast interactions with target proteins is studied, starting with compound screening and selection. The potential for fewer false positives and negatives, improved hit prediction accuracy, and ensemble technique use are underlined. The part that machine learning plays in enhancing Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profile is then explained. ML models anticipate compound actions inside the human body by analyzing molecular structures and characteristics, improving assessments of drug safety and efficacy. The article goes into further detail about predictive modeling, highlighting how machine learning may be used to find prospective therapeutic targets and confirm their applicability. The combination of multi-omics data, deep learning, and the possibility to identify similar molecular pathways across diseases highlight the game-changing potential of machine learning in this field. The article also covers the use of ML in clinical trials, highlighting its benefits for trial planning, patient recruitment, real-time monitoring, and individualized therapy predictions. By utilizing computational analysis and quantum physics, the power of machine learning-driven de novo drug creation is examined, revealing the potential to develop new therapeutic candidates. In this article, the ethical issues surrounding AI-driven drug discovery are discussed, with a focus on the necessity of transparent data utilization, human oversight, and responsible data consumption. The report ends by predicting ML's potential for pharmaceutical R&D in the future. Accelerated drug discovery pipelines, the rise of customized medicine powered by predictive models, optimized clinical trials, and a change in medication repurposing tactics are all envisaged in this. The report emphasizes the revolutionary potential of ML in altering pharmaceutical research and development while noting obstacles in data quality, model interpretability, ethics, and interdisciplinary collaboration. It is suggested that the ethical integration of AI technologies, interdisciplinary cooperation, and regulatory modifications are essential steps to unlock the full potential of ML and AI and, ultimately, provide patients throughout the world with safer, more efficient, and individualized treatments.

Google Scholar Cite Analysis
Abstract viewed = 1099 times

References

Sahu, M., Gupta, R., Ambasta, R. K., & Kumar, P. (2022). Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. Progress in Molecular Biology and Translational Science, 190(1), 57-100.

Nurmatovich, N. A., & Rustamovna, N. M. (2023). UNLOCKING THE POTENTIAL: HOW MATHEMATICAL MODELING REVOLUTIONIZES DRUG DISCOVERY AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY. World of Science, 6(6), 242-244.

Y?lmaz, A. Deep Learning and Cardiology: Revolutionizing Diagnosis, Management, and Prognosis in Cardiovascular Medicine CardioBot: Harnessing Deep Learning for Groundbreaking Innovations in Cardiac Care. All Rights Reserved It may not be reproduced in any way without the written permission of the publisher and the editor, except for short excerpts for promotion by reference. ISBN: 978-625-6925-25-0 1st Edition, 252.

Shahid, A. H., & Khattak, W. A. (2022). Improving Patient Care with Machine Learning: A Game-Changer for Healthcare. Applied Research in Artificial Intelligence and Cloud Computing, 5(1), 150-163.

Harry, A. (2023). The Future of Medicine: Harnessing the Power of AI for Revolutionizing Healthcare. International Journal of Multidisciplinary Sciences and Arts, 2(1), 36-47.

Rajula, H. S. R., Verlato, G., Manchia, M., Antonucci, N., & Fanos, V. (2020). Comparison of conventional statistical methods with machine learning in medicine: diagnosis, drug development, and treatment. Medicina, 56(9), 455.

Koromina, M., Pandi, M. T., & Patrinos, G. P. (2019). Rethinking drug repositioning and development with artificial intelligence, machine learning, and omics. Omics: a journal of integrative biology, 23(11), 539-548.

Ibrahim, M. S., & Saber, S. (2023). Machine Learning and Predictive Analytics: Advancing Disease Prevention in Healthcare. Journal of Contemporary Healthcare Analytics, 7(1), 53-71.

Shinozaki, A. (2020). Electronic medical records and machine learning in approaches to drug development. In Artificial intelligence in Oncology drug discovery and development. IntechOpen.

Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M. M., & Zhang, B. (2021). Artificial intelligence and machine learning?aided drug discovery in central nervous system diseases: State?of?the?arts and future directions. Medicinal research reviews, 41(3), 1427-1473.

Allami, R. H., & Yousif, M. G. (2023). Integrative AI-Driven Strategies for Advancing Precision Medicine in Infectious Diseases and Beyond: A Novel Multidisciplinary Approach. arXiv preprint arXiv:2307.15228.

Awad, A., Trenfield, S. J., Goyanes, A., Gaisford, S., & Basit, A. W. (2018). Reshaping drug development using 3D printing. Drug discovery today, 23(8), 1547-1555.

Ali, A. H., & Saber, S. (2022). Leveraging FAERS and Big Data Analytics with Machine Learning for Advanced Healthcare Solutions. Applied Research in Artificial Intelligence and Cloud Computing, 5(1), 121-134.

Sarkar, P. Integrating Machine Learning into Quantum Chemistry: Bridging the Gap.

Kim, R. S., Goossens, N., & Hoshida, Y. (2016). Use of big data in drug development for precision medicine. Expert review of precision medicine and drug development, 1(3), 245-253.

Vijai, C., & Wisetsri, W. (2021). Rise of artificial intelligence in healthcare startups in India. Advances In Management, 14(1), 48-52.

Nussinov, R., Zhang, M., Liu, Y., & Jang, H. (2022). AlphaFold, artificial intelligence (AI), and allostery. The Journal of Physical Chemistry B, 126(34), 6372-6383.

Handelman, G. S., Kok, H. K., Chandra, R. V., Razavi, A. H., Lee, M. J., & Asadi, H. (2018). eD octor: machine learning and the future of medicine. Journal of internal medicine, 284(6), 603-619.

Niazi, S. K., & Mariam, Z. (2023). Recent Advances in Machine-Learning-Based Chemoinformatics: A Comprehensive Review. International Journal of Molecular Sciences, 24(14), 11488.

Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., ... & Sony, H. T. (2023). Artificial intelligence and machine learning technology driven modern drug discovery and development. International Journal of Molecular Sciences, 24(3), 2026.

Malandraki-Miller, S., & Riley, P. R. (2021). Use of artificial intelligence to enhance phenotypic drug discovery. Drug Discovery Today, 26(4), 887-901.

Arora, A., & Basu, N. Machine Learning in Modern Healthcare.

Ni, D., Chai, Z., Wang, Y., Li, M., Yu, Z., Liu, Y., ... & Zhang, J. (2022). Along the allostery stream: Recent advances in computational methods for allosteric drug discovery. Wiley Interdisciplinary Reviews: Computational Molecular Science, 12(4), e1585.

Ali, H. (2023). AI-driven Drug Discovery in Bioinformatics: Accelerating Pharmaceutical Research.

YADAV, A. (2023). REVOLUTIONIZING BREAST CANCER MANAGEMENT: HARNESSING THE POWER OF MACHINE LEARNING IN DIAGNOSIS AND TREATMENT (Doctoral dissertation).

Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018). Natural products for drug discovery in the 21st century: innovations for novel drug discovery. International journal of molecular sciences, 19(6), 1578.

Uliassi, E., Gandini, A., Perone, R. C., & Bolognesi, M. L. (2017). Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery. Future medicinal chemistry, 9(10), 995-1013.

Leite, M. L., de Loiola Costa, L. S., Cunha, V. A., Kreniski, V., de Oliveira Braga Filho, M., da Cunha, N. B., & Costa, F. F. (2021). Artificial intelligence and the future of life sciences. Drug Discovery Today, 26(11), 2515-2526.

Castro, B. M., Elbadawi, M., Ong, J. J., Pollard, T., Song, Z., Gaisford, S., ... & Goyanes, A. (2021). Machine learning predicts 3D printing performance of over 900 drug delivery systems. Journal of Controlled Release, 337, 530-545.

Sarbadhikary, P., George, B. P., & Abrahamse, H. (2022). Paradigm shift in future biophotonics for imaging and therapy: Miniature living lasers to cellular scale optoelectronics. Theranostics, 12(17), 7335.

ÖZÇ?FT, A. (2023). Artificial Intelligence in Medicine and Healthcare. PIONEER AND CONTEMPORARY STUDIES IN HEALTH SCIENCES, 101-116.

Dash, S. S., Tiwari, S., & Nahak, K. (2023). REVOLUTIONIZING CARDIOVASCULAR DISEASE PREVENTION WITH MACHINE LEARNING: A COMPREHENSIVE REVIEW. Journal of Data Acquisition and Processing, 38(2), 2429.

Qian, T., Zhu, S., & Hoshida, Y. (2019). Use of big data in drug development for precision medicine: an update. Expert review of precision medicine and drug development, 4(3), 189-200.

Jayaseelan, N. AI in Healthcare Tech: Revolutionizing Medicine with Modern Applications.

Langley, G. R., Adcock, I. M., Busquet, F., Crofton, K. M., Csernok, E., Giese, C., ... & Woszczek, G. (2017). Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug discovery today, 22(2), 327-339.

Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., ... & Greene, C. S. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of The Royal Society Interface, 15(141), 20170387.

Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., ... & Merad, M. (2022). Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nature medicine, 28(4), 626-629.

Bragazzi, N. L., Bridgewood, C., Watad, A., Damiani, G., Kong, J. D., & McGonagle, D. (2022). Harnessing big data, smart and digital technologies and artificial intelligence for preventing, early intercepting, managing, and treating psoriatic arthritis: insights from a systematic review of the literature. Frontiers in Immunology, 13, 847312.

Downloads

ARTICLE Published HISTORY

Submitted Date: 2023-09-26
Accepted Date: 2023-09-26
Published Date: 2023-09-27